EIF3E

Across TCGA pan-cancer cohorts, EIF3E mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EIF3E data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher EIF3E mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EIF3E expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where EIF3E mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.859	0.493	.003	18	view →
LUAD	OS	Median	II,III,IV	0.333	0.908	.002	11	view →
PDAC	OS	Tertile	IV	0.455	0.836	.024	8	view →
CCRCC	DFS	Median	III,IV	0.573	0.837	.032	8	view →
GBM	DFS	Median	All	0.702	0.791	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EIF3E–LSCC (DFS)

Open the LSCC breakdown →